A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas
Infante, Jeffrey R, Somer, Bradley G, Park, Joon Oh, Li, Chung-Pin, Scheulen, Max E, Kasubhai, Saifuddin M, Oh, Do-Youn, Liu, Yuan, Redhu, Suman, Steplewski, Klaudia, Le, Ngocdiep
Published in European journal of cancer (1990) (01.08.2014)
Published in European journal of cancer (1990) (01.08.2014)
Get full text
Journal Article
Phase Ib study of dulanermin combined with FOLFIRI (with or without bevacizumab [BV]) in previously treated patients (Pts) with metastatic colorectal cancer (mCRC)
Kasubhai, Saifuddin M., Bendell, Johanna C., Kozloff, Mark, Kapp, Amy V., Ashkenazi, Avi, Royer-Joo, Stephanie, Portera, Chia C.
Published in Journal of clinical oncology (20.05.2012)
Published in Journal of clinical oncology (20.05.2012)
Get full text
Journal Article
A randomized, double-blind, placebo-controlled trial of trametinib, a MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas
Infante, Jeffrey R., Somer, Bradley G., Park, Joon Oh, Li, Chung-Pin, Scheulen, Max E., Kasubhai, Saifuddin M., Oh, Do-Youn, Liu, Yuan, Lahiri, Soumi, Steplewski, Klaudia, Le, Ngocdiep T.
Published in Journal of clinical oncology (01.02.2013)
Published in Journal of clinical oncology (01.02.2013)
Get full text
Journal Article